

Angelo Corti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2822775/publications.pdf>

Version: 2024-02-01

208
papers

10,320
citations

31976

53
h-index

42399

92
g-index

210
all docs

210
docs citations

210
times ranked

8816
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Tumor Necrosis Factor Soluble Receptors in Patients With Various Degrees of Congestive Heart Failure. <i>Circulation</i> , 1995, 92, 1479-1486. | 1.6 | 452 |
| 2 | Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1985, 82, 4939-4943. | 7.1 | 427 |
| 3 | Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). <i>Nature Biotechnology</i> , 2000, 18, 1185-1190. | 17.5 | 403 |
| 4 | Autocrine saturation of pro-urokinase receptors on human A431 cells. <i>Cell</i> , 1986, 45, 675-684. | 28.9 | 364 |
| 5 | Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. <i>Cancer Research</i> , 2003, 63, 7400-9. | 0.9 | 242 |
| 6 | Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. <i>Cancer Research</i> , 2002, 62, 867-74. | 0.9 | 217 |
| 7 | Targeting Liposomal Chemotherapy via Both Tumor Cell-Specific and Tumor Vasculature-Specific Ligands Potentiates Therapeutic Efficacy. <i>Cancer Research</i> , 2006, 66, 10073-10082. | 0.9 | 215 |
| 8 | Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. <i>Journal of Clinical Investigation</i> , 2002, 110, 475-482. | 8.2 | 206 |
| 9 | Chromogranin A in heart failure. A novel neurohumoral factor and a predictor for mortality. <i>European Heart Journal</i> , 2002, 23, 967-974. | 2.2 | 189 |
| 10 | The endocrine role for chromogranin A: A prohormone for peptides with regulatory properties. <i>Cellular and Molecular Life Sciences</i> , 2007, 64, 2863-2886. | 5.4 | 185 |
| 11 | The neovasculature homing motif NGR: more than meets the eye. <i>Blood</i> , 2008, 112, 2628-2635. | 1.4 | 181 |
| 12 | Spontaneous Formation of L-Isoaspartate and Gain of Function in Fibronectin. <i>Journal of Biological Chemistry</i> , 2006, 281, 36466-36476. | 3.4 | 176 |
| 13 | Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. <i>European Heart Journal</i> , 2007, 28, 1117-1127. | 2.2 | 160 |
| 14 | Structure-Activity Relationships of Linear and Cyclic Peptides Containing the NGR Tumor-homing Motif. <i>Journal of Biological Chemistry</i> , 2002, 277, 47891-47897. | 3.4 | 159 |
| 15 | Antibacterial and Antifungal Activities of Vasostatin-1, the N-terminal Fragment of Chromogranin A. <i>Journal of Biological Chemistry</i> , 2000, 275, 10745-10753. | 3.4 | 144 |
| 16 | Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor- α . <i>Clinical Cancer Research</i> , 2006, 12, 175-182. | 7.0 | 141 |
| 17 | Coupling Tumor Necrosis Factor- α with α V Integrin Ligands Improves Its Antineoplastic Activity. <i>Cancer Research</i> , 2004, 64, 565-571. | 0.9 | 134 |
| 18 | Targeting TNF- α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy. <i>Journal of Immunology</i> , 2012, 188, 2687-2694. | 0.8 | 128 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Teicoplanin, a new antibiotic from <i>Actinoplanes teichomyceticus</i> nov. sp. <i>Antimicrobial Agents and Chemotherapy</i> , 1984, 26, 917-923. | 3.2 | 118 |
| 20 | Oligomeric tumour necrosis factor $\hat{\pm}$ slowly converts into inactive forms at bioactive levels. <i>Biochemical Journal</i> , 1992, 284, 905-910. | 3.7 | 117 |
| 21 | Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. <i>Journal of Clinical Investigation</i> , 2002, 110, 475-482. | 8.2 | 111 |
| 22 | Targeted Drug Delivery and Penetration Into Solid Tumors. <i>Medicinal Research Reviews</i> , 2012, 32, 1078-1091. | 10.5 | 108 |
| 23 | Chromogranin A protects vessels against tumor necrosis factor $\hat{\pm}$ -induced vascular leakage. <i>FASEB Journal</i> , 2004, 18, 554-556. | 0.5 | 102 |
| 24 | Structural Basis for the Interaction of isoDGR with the RGD-binding Site of $\hat{\pm}$ $\hat{\nu}$ $\hat{\nu}$ $\hat{3}$ Integrin. <i>Journal of Biological Chemistry</i> , 2008, 283, 19757-19768. | 3.4 | 93 |
| 25 | Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. <i>Cell Reports</i> , 2016, 14, 1748-1760. | 6.4 | 90 |
| 26 | Chromogranin A Induces a Neurotoxic Phenotype in Brain Microglial Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 14339-14346. | 3.4 | 88 |
| 27 | Targeted Delivery of IFN $\hat{\nu}$ $\hat{3}$ to Tumor Vessels Uncouples Antitumor from Counterregulatory Mechanisms. <i>Cancer Research</i> , 2005, 65, 2906-2913. | 0.9 | 87 |
| 28 | Enhanced Antitumor Efficacy of Clinical-Grade Vasculature-Targeted Liposomal Doxorubicin. <i>Clinical Cancer Research</i> , 2008, 14, 7320-7329. | 7.0 | 82 |
| 29 | Roles of tumor necrosis factor p55 and p75 receptors in TNF- $\hat{\pm}$ -induced vascular permeability. <i>American Journal of Physiology - Cell Physiology</i> , 2001, 281, C1173-C1179. | 4.6 | 80 |
| 30 | Tumor Necrosis Factor $\hat{\pm}$ As a Master Regulator of Inflammation in Erdheim-Chester Disease: Rationale for the Treatment of Patients With Infliximab. <i>Journal of Clinical Oncology</i> , 2012, 30, e286-e290. | 1.6 | 79 |
| 31 | Tumor Vascular Targeting with Tumor Necrosis Factor $\hat{\pm}$ and Chemotherapeutic Drugs. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 104-112. | 3.8 | 78 |
| 32 | Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. <i>Journal of Controlled Release</i> , 2010, 145, 66-73. | 9.9 | 78 |
| 33 | How to improve exposure of tumor cells to drugs $\hat{\pm}$ Promoter drugs increase tumor uptake and penetration of effector drugs. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 53-68. | 13.7 | 78 |
| 34 | Critical Role of Flanking Residues in NGR-to-isoDGR Transition and CD13/Integrin Receptor Switching. <i>Journal of Biological Chemistry</i> , 2010, 285, 9114-9123. | 3.4 | 77 |
| 35 | Chromogranin A and Derived Peptides in Health and Disease. <i>Journal of Molecular Neuroscience</i> , 2012, 48, 347-356. | 2.3 | 76 |
| 36 | The vasostatin- $\hat{\nu}$ fragment of chromogranin A inhibits VEGF- $\hat{\nu}$ -induced endothelial cell proliferation and migration. <i>FASEB Journal</i> , 2007, 21, 3052-3062. | 0.5 | 75 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Isoaspartate-dependent molecular switches for integrin α 5 β 1 ligand recognition. <i>Journal of Cell Science</i> , 2011, 124, 515-522. | 2.0 | 75 |
| 38 | Chromogranin A Fragments Modulate Cell Adhesion. <i>Journal of Biological Chemistry</i> , 1997, 272, 20835-20843. | 3.4 | 71 |
| 39 | Overexpression of the hereditary hemochromatosis protein, HFE, in HeLa cells induces an iron-deficient phenotype. <i>FEBS Letters</i> , 1999, 460, 149-152. | 2.8 | 71 |
| 40 | Isoaspartate-Glycine-Arginine: A New Tumor Vasculature α 5 β 1 Targeting Motif. <i>Cancer Research</i> , 2008, 68, 7073-7082. | 0.9 | 71 |
| 41 | Structure-Activity Relationships of Chromogranin A in Cell Adhesion. <i>Journal of Biological Chemistry</i> , 2000, 275, 29257-29263. | 3.4 | 70 |
| 42 | A new chromogranin A α 5 β 1 dependent angiogenic switch activated by thrombin. <i>Blood</i> , 2013, 121, 392-402. | 1.4 | 68 |
| 43 | Tumor Necrosis Factor (TNF) α 1 quantification by ELISA and bioassay: effects of TNF α -soluble TNF receptor (p55) complex dissociation during assay incubations. <i>Journal of Immunological Methods</i> , 1994, 177, 191-198. | 1.4 | 67 |
| 44 | Crucial Role for Interferon γ in the Synergism between Tumor Vasculature-Targeted Tumor Necrosis Factor α 1 (NGR-TNF) and Doxorubicin. <i>Cancer Research</i> , 2004, 64, 7150-7155. | 0.9 | 66 |
| 45 | Recombinant N α 1-terminal fragments of chromogranin α 5 β 1 modulate cardiac function of the Langendorff α 5 β 1 perfused rat heart. <i>Basic Research in Cardiology</i> , 2006, 101, 43-52. | 5.9 | 66 |
| 46 | Granin-derived peptides. <i>Progress in Neurobiology</i> , 2017, 154, 37-61. | 5.7 | 65 |
| 47 | Influence of vasostatin, the chromogranin A-derived peptides, on the working heart of the eel (<i>Anguilla anguilla</i>): negative inotropy and mechanism of action. <i>General and Comparative Endocrinology</i> , 2004, 139, 20-28. | 1.8 | 64 |
| 48 | Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation. <i>Annals of the New York Academy of Sciences</i> , 2019, 1455, 34-58. | 3.8 | 64 |
| 49 | The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells. <i>Regulatory Peptides</i> , 2006, 135, 78-84. | 1.9 | 63 |
| 50 | Peptide-Mediated Targeting of Cytokines to Tumor Vasculature: The NGR-hTNF Example. <i>BioDrugs</i> , 2013, 27, 591-603. | 4.6 | 63 |
| 51 | Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 1128-1134. | 1.6 | 62 |
| 52 | Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H719-H727. | 3.2 | 60 |
| 53 | Chromogranin A N-terminal fragments vasostatin-1 and the synthetic CGA 7 α 5 β 1 peptide act as cardiostatsins on the isolated working frog heart. <i>General and Comparative Endocrinology</i> , 2004, 136, 217-224. | 1.8 | 59 |
| 54 | Catestatin Inhibits Obesity-Induced Macrophage Infiltration and Inflammation in the Liver and Suppresses Hepatic Glucose Production, Leading to Improved Insulin Sensitivity. <i>Diabetes</i> , 2018, 67, 841-848. | 0.6 | 58 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Enhanced Expression of CD13 in Vessels of Inflammatory and Neoplastic Tissues. <i>Journal of Histochemistry and Cytochemistry</i> , 2011, 59, 47-59. | 2.5 | 56 |
| 56 | Inhibition of Tumor Growth by Intramuscular Injection of cDNA Encoding Tumor Necrosis Factor- β Coupled to NGR and RGD Tumor-Homing Peptides. <i>Human Gene Therapy</i> , 2004, 15, 373-382. | 2.7 | 54 |
| 57 | Tumor cell-associated immune checkpoint molecules – Drivers of malignancy and stemness. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 571-583. | 7.4 | 54 |
| 58 | The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscinigraphy and radioimmunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 350-351. | 2.1 | 53 |
| 59 | Tumor necrosis factor in congestive heart failure: A mechanism of disease for the new millennium?. <i>Progress in Cardiovascular Diseases</i> , 1998, 41, 25-30. | 3.1 | 52 |
| 60 | Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF- β -elicited endothelial activation. <i>Journal of Leukocyte Biology</i> , 2009, 85, 81-87. | 3.3 | 52 |
| 61 | Pushing tumor cells towards a malignant phenotype: Stimuli from the microenvironment, intercellular communications and alternative roads. <i>International Journal of Cancer</i> , 2014, 135, 1265-1276. | 5.1 | 51 |
| 62 | Chromogranin A and Tumor Necrosis Factor- β (TNF) in Chronic Heart Failure. , 2000, 482, 351-359. | | 50 |
| 63 | Characterization of natural vasostatin-containing peptides in rat heart. <i>FEBS Journal</i> , 2006, 273, 3311-3321. | 4.7 | 50 |
| 64 | Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. <i>European Journal of Cancer</i> , 2010, 46, 198-206. | 2.8 | 50 |
| 65 | Tumor necrosis factor β and its receptors in relapsing-remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1997, 152, 51-61. | 0.6 | 49 |
| 66 | Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. <i>Molecular Immunology</i> , 2006, 43, 1509-1518. | 2.2 | 49 |
| 67 | NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors. <i>Nano Research</i> , 2016, 9, 1393-1408. | 10.4 | 48 |
| 68 | Vasculature-targeted tumor necrosis factor- α increases the therapeutic index of doxorubicin against prostate cancer. <i>Prostate</i> , 2008, 68, 1105-1115. | 2.3 | 47 |
| 69 | Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. <i>MAbs</i> , 2013, 5, 34-46. | 5.2 | 46 |
| 70 | Synergistic Damage of Tumor Vessels with Ultra Low-Dose Endothelial-Monocyte Activating Polypeptide-II and Neovasculature-Targeted Tumor Necrosis Factor- β . <i>Cancer Research</i> , 2008, 68, 1154-1161. | 0.9 | 45 |
| 71 | Chromogranin A and the Tumor Microenvironment. <i>Cellular and Molecular Neurobiology</i> , 2010, 30, 1163-1170. | 3.3 | 45 |
| 72 | Synthesis and characterization of D-Alanyl-D-Alanine-Agarose. <i>Applied Biochemistry and Biotechnology</i> , 1985, 11, 101-109. | 2.9 | 44 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Production and Structure Characterization of Recombinant Chromogranin A N-Terminal Fragments (Vasostatsins). Evidence of Dimmer-Monomer Equilibria. <i>FEBS Journal</i> , 1997, 248, 692-699. | 0.2 | 44 |
| 74 | Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. <i>Investigational New Drugs</i> , 2006, 24, 27-36. | 2.6 | 43 |
| 75 | Selective Imaging of the Angiogenic Relevant Integrins $\alpha_5\beta_1$ and $\alpha_v\beta_3$. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 11656-11659. | 13.8 | 43 |
| 76 | R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor- α in primary CNS lymphoma. <i>Blood</i> , 2019, 134, 252-262. | 1.4 | 43 |
| 77 | Conversation galante: How the immune and the neuroendocrine systems talk to each other. <i>Autoimmunity Reviews</i> , 2007, 7, 23-29. | 5.8 | 42 |
| 78 | Full-Length Human Chromogranin-A Cardioactivity: Myocardial, Coronary, and Stimulus-Induced Processing Evidence in Normotensive and Hypertensive Male Rat Hearts. <i>Endocrinology</i> , 2013, 154, 3353-3365. | 2.8 | 41 |
| 79 | Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings. <i>Journal of Controlled Release</i> , 2013, 170, 233-241. | 9.9 | 41 |
| 80 | Chromogranin A: a paradoxical player in angiogenesis and vascular biology. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 339-348. | 5.4 | 41 |
| 81 | CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study. <i>Molecular Medicine</i> , 2021, 27, 129. | 4.4 | 41 |
| 82 | Interactions of chromogranin A-derived vasostatsins and monolayers of phosphatidylserine, phosphatidylcholine and phosphatidylethanolamine. <i>Regulatory Peptides</i> , 2006, 134, 30-37. | 1.9 | 40 |
| 83 | Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 2171-2181. | 7.0 | 40 |
| 84 | Chromogranin A expression in neoplastic cells affects tumor growth and morphogenesis in mouse models. <i>Cancer Research</i> , 2002, 62, 941-6. | 0.9 | 39 |
| 85 | Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. <i>Cancer</i> , 2007, 110, 845-853. | 4.1 | 38 |
| 86 | Antigenic Regions of Human Chromogranin A and their Topographic Relationships with Structural/Functional Domains. <i>FEBS Journal</i> , 1996, 235, 275-280. | 0.2 | 37 |
| 87 | Induction of functional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor- α . <i>European Heart Journal</i> , 1999, 20, 1503-1513. | 2.2 | 37 |
| 88 | Biochemical characterization and crystal structure of a recombinant hen avidin and its acidic mutant expressed in <i>Escherichia coli</i> . <i>FEBS Journal</i> , 1998, 256, 453-460. | 0.2 | 36 |
| 89 | Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion. <i>Biomaterials</i> , 2015, 68, 89-99. | 11.4 | 36 |
| 90 | Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers. <i>Pflügers Archiv European Journal of Physiology</i> , 2018, 470, 199-210. | 2.8 | 36 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Monoclonal antibodies to human urokinase identify the single-chain pro-urokinase precursor. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 110-114. | 7.1 | 35 |
| 92 | CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20717-20722. | 7.1 | 35 |
| 93 | Ceruloplasmin functional changes in Parkinson's disease-cerebrospinal fluid. Molecular Neurodegeneration, 2015, 10, 59. | 10.8 | 35 |
| 94 | Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2223-2228. | 7.1 | 35 |
| 95 | Neuroendocrine Modulation Induced by Selective Blockade of TNF- α in Rheumatoid Arthritis. Annals of the New York Academy of Sciences, 2006, 1069, 428-437. | 3.8 | 34 |
| 96 | The vasostatin-1 fragment of chromogranin A preserves a quiescent phenotype in hypoxia-driven endothelial cells and regulates tumor neovascularization. FASEB Journal, 2011, 25, 3906-3914. | 0.5 | 34 |
| 97 | Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers. Small, 2019, 15, e1804591. | 10.0 | 34 |
| 98 | IsoDGR-tagged Albumin: A New α 2 Selective Carrier for Nanodrug Delivery to Tumors. Small, 2013, 9, 673-678. | 10.0 | 33 |
| 99 | Characterisation of circulating chromogranin A in human cancer patients. British Journal of Cancer, 1996, 73, 924-932. | 6.4 | 32 |
| 100 | Cleavage of Chromogranin A N-terminal Domain by Plasmin Provides a New Mechanism for Regulating Cell Adhesion. Journal of Biological Chemistry, 2002, 277, 45911-45919. | 3.4 | 32 |
| 101 | Peptide microarrays for the characterization of antigenic regions of human chromogranin A. Proteomics, 2005, 5, 3600-3603. | 2.2 | 32 |
| 102 | Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. Trends in Immunology, 2008, 29, 235-241. | 6.8 | 32 |
| 103 | Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. Journal of Clinical Investigation, 2002, 110, 475-482. | 8.2 | 32 |
| 104 | Regulation of Endothelial Cell Shape and Barrier Function by Chromogranin A. Annals of the New York Academy of Sciences, 2002, 971, 355-358. | 3.8 | 31 |
| 105 | Comparison of the solid phase enzyme receptor assay (SPERA) and the microbiological assay for teicoplanin. Journal of Hospital Infection, 1986, 7, 85-89. | 2.9 | 30 |
| 106 | T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNF- α Expression and Empower Adoptive Cell Therapy for Solid Tumors. Cancer Research, 2017, 77, 658-671. | 0.9 | 30 |
| 107 | TNF- α Coupled to Membrane of Apoptotic Cells Favors the Cross-Priming to Melanoma Antigens. Journal of Immunology, 2004, 172, 2643-2650. | 0.8 | 28 |
| 108 | Oxidation-induced Structural Changes of Ceruloplasmin Foster NGR Motif Deamidation That Promotes Integrin Binding and Signaling. Journal of Biological Chemistry, 2014, 289, 3736-3748. | 3.4 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Chromogranin A Regulates Tumor Self-Seeding and Dissemination. <i>Cancer Research</i> , 2012, 72, 449-459. | 0.9 | 27 |
| 110 | Improving drug penetration to curb tumor drug resistance. <i>Drug Discovery Today</i> , 2012, 17, 1139-1146. | 6.4 | 27 |
| 111 | Binding of human tumor necrosis factor $\hat{\pm}$ to multimeric complementary peptides. <i>Archives of Biochemistry and Biophysics</i> , 1992, 296, 137-143. | 3.0 | 26 |
| 112 | Kinetic analysis of TNF- $\hat{\pm}$ oligomer-monomer transition by surface plasmon resonance and immunochemical methods. <i>Cytokine</i> , 1993, 5, 539-545. | 3.2 | 26 |
| 113 | Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFN $\hat{\alpha}$. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3859-3866. | 4.1 | 25 |
| 114 | Vasostatin-I, a chromogranin A-derived peptide, in non-selected critically ill patients: distribution, kinetics, and prognostic significance. <i>Intensive Care Medicine</i> , 2012, 38, 1514-1522. | 8.2 | 24 |
| 115 | pGlu-serpinin protects the normotensive and hypertensive heart from ischemic injury. <i>Journal of Endocrinology</i> , 2015, 227, 167-178. | 2.6 | 24 |
| 116 | Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients. <i>Cancer Research</i> , 2016, 76, 1781-1791. | 0.9 | 24 |
| 117 | Chromogranin A regulates vesicle storage and mitochondrial dynamics to influence insulin secretion. <i>Cell and Tissue Research</i> , 2017, 368, 487-501. | 2.9 | 24 |
| 118 | Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. <i>Blood Advances</i> , 2020, 4, 3648-3658. | 5.2 | 24 |
| 119 | Chromogranin A Restricts Drug Penetration and Limits the Ability of NGR-TNF to Enhance Chemotherapeutic Efficacy. <i>Cancer Research</i> , 2011, 71, 5881-5890. | 0.9 | 23 |
| 120 | A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma. <i>Oncolmmunology</i> , 2014, 3, e963406. | 4.6 | 23 |
| 121 | Enhancement of Tumor Homing by Chemotherapy-Loaded Nanoparticles. <i>Small</i> , 2018, 14, e1802886. | 10.0 | 23 |
| 122 | NF- $\hat{\rho}$ B-mediated regulation of urokinase gene expression by PMA and TNF- $\hat{\pm}$ in human A549 cells. <i>FEBS Letters</i> , 1996, 393, 69-73. | 2.8 | 22 |
| 123 | Affinity enhancement of complementary peptide recognition. <i>International Journal of Peptide and Protein Research</i> , 1992, 39, 549-556. | 0.1 | 22 |
| 124 | Inverse Polymerase Chain Reaction for Cloning Complete Human Immunoglobulin Variable Regions and Leaders Conserving the Original Sequence. <i>Analytical Biochemistry</i> , 1996, 239, 107-109. | 2.4 | 21 |
| 125 | Crucial role of cytoskeleton reorganization in the negative inotropic effect of chromogranin A-derived peptides in eel and frog hearts. <i>Regulatory Peptides</i> , 2007, 138, 145-151. | 1.9 | 21 |
| 126 | High blood levels of chromogranin A in giant cell arteritis identify patients refractory to corticosteroid treatment. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 293-295. | 0.9 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 127 | Wonâ€™t you come on in? How to favor lymphocyte infiltration in tumors. <i>Oncolmunology</i> , 2012, 1, 986-988. | 4.6 | 21 |
| 128 | Chromogranin-A production and fragmentation in patients with Takayasu arteritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 187. | 3.5 | 21 |
| 129 | Boosting Interleukinâ€™12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGRâ€™Tagged Nanogold. <i>Small</i> , 2019, 15, e1903462. | 10.0 | 21 |
| 130 | Purification and Characterization of Single-Chain Urokinase-Type Plasminogen Activator (Pro-Urokinase) from Human A431 Cells. <i>Thrombosis and Haemostasis</i> , 1986, 56, 219-224. | 3.4 | 21 |
| 131 | Physiological levels of chromogranin A prevent doxorubicinâ€™induced cardiotoxicity without impairing its anticancer activity. <i>FASEB Journal</i> , 2019, 33, 7734-7747. | 0.5 | 20 |
| 132 | Glycine N-Methylation in NGRâ€™Tagged Nanocarriers Prevents Isoaspartate Formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing. <i>Advanced Functional Materials</i> , 2017, 27, 1701245. | 14.9 | 19 |
| 133 | Succinimide-Based Conjugates Improve IsoDGR Cyclopeptide Affinity to \hat{v}^3 without Promoting Integrin Allosteric Activation. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7474-7485. | 6.4 | 19 |
| 134 | Breaching the Bloodâ€™Brain Tumor Barrier for Tumor Therapy. <i>Cancers</i> , 2021, 13, 2391. | 3.7 | 19 |
| 135 | Chromogranin A and the Endothelial Barrier Function. <i>Current Medicinal Chemistry</i> , 2012, 19, 4051-4058. | 2.4 | 18 |
| 136 | Regulation of tumor growth by circulating full-length chromogranin A. <i>Oncotarget</i> , 2016, 7, 72716-72732. | 1.8 | 18 |
| 137 | Inhibitory influence of chromogranin A N-terminal fragment (vasostatin-1) on the spontaneous contractions of rat proximal colon. <i>Regulatory Peptides</i> , 2005, 130, 42-47. | 1.9 | 17 |
| 138 | Chromogranin A binds to \hat{v}^26 -integrin and promotes wound healing in mice. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 2791-2803. | 5.4 | 17 |
| 139 | Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis. <i>Experimental Cell Research</i> , 2015, 330, 1-12. | 2.6 | 17 |
| 140 | Role of vasostatin-1 C-terminal region in fibroblast cell adhesion. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 2107-2118. | 5.4 | 16 |
| 141 | Oxidative stress biomarkers and chromogranin A in uremic patients: Effects of dialytic treatment. <i>Clinical Biochemistry</i> , 2010, 43, 1387-1392. | 1.9 | 16 |
| 142 | Processing of chromogranins/secretogranin in patients with diabetic retinopathy. <i>Regulatory Peptides</i> , 2011, 167, 118-124. | 1.9 | 16 |
| 143 | TNF- \hat{A} in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. <i>Rheumatology</i> , 2014, 53, 198-200. | 1.9 | 16 |
| 144 | Effect of chromogranin Aâ€™derived vasostatinâ€™1 on laserâ€™induced choroidal neovascularization in the mouse. <i>Acta Ophthalmologica</i> , 2015, 93, e218-22. | 1.1 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | The chromogranin A- derived N-terminal peptide vasostatin-I: In vivo effects on cardiovascular variables in the rabbit. <i>Regulatory Peptides</i> , 2011, 168, 10-20. | 1.9 | 15 |
| 146 | Identification of Two Forms (31-33 and 48 kD) of the Urinary Soluble p55 Tumor Necrosis Factor Receptor That Are Differentially N- and O-Glycosylated. <i>Journal of Interferon and Cytokine Research</i> , 1995, 15, 143-152. | 1.2 | 14 |
| 147 | Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. <i>OncolImmunology</i> , 2016, 5, e1181244. | 4.6 | 14 |
| 148 | The chromogranin A 1-373 fragment reveals how a single change in the protein sequence exerts strong cardioregulatory effects by engaging neuropilin-1. <i>Acta Physiologica</i> , 2021, 231, e13570. | 3.8 | 14 |
| 149 | Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms. <i>PLoS ONE</i> , 2018, 13, e0196858. | 2.5 | 14 |
| 150 | Chapter 12 Liposome-Mediated Therapy of Neuroblastoma. <i>Methods in Enzymology</i> , 2009, 465, 225-249. | 1.0 | 13 |
| 151 | Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF. <i>Journal of Oncology</i> , 2010, 2010, 1-8. | 1.3 | 13 |
| 152 | Enhancement of doxorubicin anti-cancer activity by vascular targeting using IsoDGR/cytokine-coated nanogold. <i>Journal of Nanobiotechnology</i> , 2021, 19, 128. | 9.1 | 13 |
| 153 | Upregulation of p75 Tumor Necrosis Factor Alpha Receptor in <i>Mycobacterium avium</i> -Infected Mice: Evidence for a Functional Role. <i>Infection and Immunity</i> , 1999, 67, 5762-5767. | 2.2 | 13 |
| 154 | Long human <i>CHGA</i> flanking chromosome 14 sequence required for optimal BAC transgenic rescue of disease phenotypes in the mouse <i>Chga</i> knockout. <i>Physiological Genomics</i> , 2010, 41, 91-101. | 2.3 | 12 |
| 155 | Cytoskeleton mediates negative inotropism and lusitropism of chromogranin A-derived peptides (human vasostatin1-78 and rat CgA1-64) in the rat heart. <i>Regulatory Peptides</i> , 2010, 165, 78-85. | 1.9 | 12 |
| 156 | The N-Terminal Fragment of Chromogranin A, Vasostatin-1 Protects Mice From Acute or Chronic Colitis Upon Oral Administration. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1227-1237. | 2.3 | 12 |
| 157 | Production of Soluble Tumor Necrosis Factor Receptor Type I in <i>Escherichia coli</i> : Optimization of the Refolding Yields by a Microtiter Dilution Assay. <i>Analytical Biochemistry</i> , 1995, 230, 85-91. | 2.4 | 11 |
| 158 | Effect of bench-scale culture conditions on murine IgG heterogeneity. , 1997, 54, 17-25. | | 11 |
| 159 | Strategies for Improving the Anti-Neoplastic Activity of TNF by Tumor Targeting. , 2004, 98, 247-264. | | 11 |
| 160 | Plasma levels of vasostatin-1, a chromogranin A fragment, are associated with carotid artery maximum stenosis: A pilot study. <i>International Journal of Cardiology</i> , 2017, 236, 438-443. | 1.7 | 11 |
| 161 | Catestatin regulates vesicular quanta through modulation of cholinergic and peptidergic (PACAPergic) stimulation in PC12 cells. <i>Cell and Tissue Research</i> , 2019, 376, 51-70. | 2.9 | 11 |
| 162 | Differential Detection of Single-Chain and Two-Chain Urokinase-Type Plasminogen Activator by a New Immunoabsorbent-Amidolytic Assay (IAA). <i>Thrombosis and Haemostasis</i> , 1986, 56, 407-410. | 3.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | The Importance of Detail: How Differences in Ligand Structures Determine Distinct Functional Responses in Integrin $\alpha 3$. <i>Chemistry - A European Journal</i> , 2019, 25, 5959-5970. | 3.3 | 10 |
| 164 | A Pilot Study on Continuous Infusion of 4% Albumin in Critically Ill Patients. , 2019, 1, e0044. | | 10 |
| 165 | Spatiotemporal Regulation of Tumor Angiogenesis by Circulating Chromogranin A Cleavage and Neuropilin-1 Engagement. <i>Cancer Research</i> , 2019, 79, 1925-1937. | 0.9 | 9 |
| 166 | Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models. <i>Oncotarget</i> , 0, 7, 41725-41736. | 1.8 | 9 |
| 167 | Chromogranin A plasma levels predict mortality in COVID-19. <i>PLoS ONE</i> , 2022, 17, e0267235. | 2.5 | 9 |
| 168 | Antigenic regions of tumor necrosis factor alpha and their topographic relationships with structural/functional domains. <i>Molecular Immunology</i> , 1992, 29, 471-479. | 2.2 | 8 |
| 169 | Idiotope determining regions of a mouse monoclonal antibody and its humanized versions. <i>Journal of Molecular Biology</i> , 1994, 235, 53-60. | 4.2 | 8 |
| 170 | Biotinylation Sites of Tumor Necrosis Factor- α Determined by Liquid Chromatography-Mass Spectrometry. <i>Analytical Biochemistry</i> , 2001, 298, 181-188. | 2.4 | 8 |
| 171 | Development of an immunoassay for the derived-peptide of chromogranin A, Vasostatin-I (1-76): assessment of severity in patients with sepsis. <i>Biomarkers</i> , 2012, 17, 430-434. | 1.9 | 8 |
| 172 | Altered Chromogranin A Circulating Levels in Meniere's Disease. <i>Disease Markers</i> , 2015, 2015, 1-6. | 1.3 | 8 |
| 173 | Muscle injury, impaired muscle function and insulin resistance in Chromogranin A-knockout mice. <i>Journal of Endocrinology</i> , 2017, 232, 137-153. | 2.6 | 8 |
| 174 | Chromogranin A in Tumors: More Than a Marker for Diagnosis and Prognosis. <i>Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents</i> , 2004, 4, 161-168. | 0.2 | 8 |
| 175 | Production and Characterization of Recombinant Human and Murine TNF. , 2004, 98, 009-022. | | 7 |
| 176 | Mode of Interaction Between Tumor Necrosis Factor α and a Monoclonal Antibody Expressing a Recurrent Idiotype. <i>Hybridoma</i> , 1993, 12, 1-13. | 0.6 | 6 |
| 177 | Vascular attack and immunotherapy: a "two hits" approach to improve biological treatment of cancer. <i>Gene Therapy</i> , 1999, 6, 153-154. | 4.5 | 6 |
| 178 | Characterisation of functional biotinylated TNF- α targeted to the membrane of apoptotic melanoma cells. <i>Journal of Immunological Methods</i> , 2003, 276, 79-87. | 1.4 | 6 |
| 179 | Human Recombinant Vasostatin-1 May Interfere with Cell-Extracellular Matrix Interactions. <i>Annals of the New York Academy of Sciences</i> , 2006, 1090, 305-310. | 3.8 | 6 |
| 180 | Improving Drug Uptake and Penetration into Tumors: Current and Forthcoming Opportunities. <i>Frontiers in Oncology</i> , 2013, 3, 161. | 2.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 181 | Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 49-56. | 1.5 | 6 |
| 182 | Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET). <i>Pancreatology</i> , 2019, 19, 57-63. | 1.1 | 6 |
| 183 | NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity. <i>Molecular Pharmaceutics</i> , 2020, 17, 3813-3824. | 4.6 | 6 |
| 184 | Epitope Mapping of Human Chromogranin A by Peptide Microarrays. <i>Methods in Molecular Biology</i> , 2009, 570, 221-232. | 0.9 | 6 |
| 185 | Bone marrow-derived CD13+ cells sustain tumor progression. <i>Oncolmmunology</i> , 2014, 3, e27716. | 4.6 | 5 |
| 186 | Targeting CD13 with Asn-Gly-Arg (NGR) Peptide-Drug Conjugates. , 2017, , 101-122. | | 5 |
| 187 | A stapled chromogranin A-derived peptide is a potent dual ligand for integrins $\alpha 26$ and $\alpha 28$. <i>Chemical Communications</i> , 2019, 55, 14777-14780. | 4.1 | 5 |
| 188 | PCR amplification of antibody variable regions using primers that anneal to constant regions. <i>Nucleic Acids Research</i> , 1994, 22, 1768-1769. | 14.5 | 4 |
| 189 | Targeting the Blood-Brain Tumor Barrier with Tumor Necrosis Factor- α . <i>Pharmaceutics</i> , 2022, 14, 1414. | 4.5 | 4 |
| 190 | Rapid and simple DNA detection by hybridization on absorbent filters. <i>Nucleic Acids Research</i> , 1991, 19, 1351-1351. | 14.5 | 3 |
| 191 | Post cardiac surgery diaphragmatic spasm successfully treated with gabapentin. <i>International Journal of Cardiology</i> , 2006, 109, 282-283. | 1.7 | 3 |
| 192 | Abstract 4387: Anti-tumor activity of TNF-gold nanodrugs tagged with tumor vasculature-homing peptides containing the NGR or isoDGR motives. <i>Cancer Research</i> , 2015, 75, 4387-4387. | 0.9 | 3 |
| 193 | A Novel RGD-4C-Saporin Conjugate Inhibits Tumor Growth in Mouse Models of Bladder Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 846958. | 2.8 | 3 |
| 194 | A rapid method for monitoring DNA labelling reactions with haptens. <i>Journal of Immunological Methods</i> , 1990, 134, 81-86. | 1.4 | 2 |
| 195 | Evidences that syngeneic alpha-type anti-idiotypic antibodies may non-competitively inhibit idioype/oligomeric antigen interactions by affecting idioype avidity. <i>Molecular Immunology</i> , 1993, 30, 1123-1131. | 2.2 | 2 |
| 196 | Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 613582. | 2.8 | 2 |
| 197 | Nanogold Functionalized With Lipoamide-isoDGR: A Simple, Robust and Versatile Nanosystem for $\alpha 3$ -Integrin Targeting. <i>Frontiers in Chemistry</i> , 2021, 9, 690357. | 3.6 | 2 |
| 198 | Oral direct thrombin inhibition: a double-edged sword?. <i>Heart, Lung and Vessels</i> , 2015, 7, 191-7. | 0.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 199 | CgA in heart diseases: more than meets the eye. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 90. | 11.4 | 1 |
| 200 | Mode of interaction between a monoclonal antibody and human TNF α . <i>Pharmacological Research</i> , 1992, 26, 144-145. | 7.1 | 0 |
| 201 | Chromogranin A and its peptide fragments in tumour biology. <i>Regulatory Peptides</i> , 2010, 164, 20-21. | 1.9 | 0 |
| 202 | Commentary: Granins, Secretory Granule Biogenesis, and Transport. <i>Journal of Molecular Neuroscience</i> , 2012, 48, 315-316. | 2.3 | 0 |
| 203 | Chromogranin A in Endothelial Homeostasis and Angiogenesis. <i>UNIPA Springer Series</i> , 2017, , 83-98. | 0.1 | 0 |
| 204 | Abstract 1414: Regulation of tumor cell trafficking by chromogranin A. , 2012, , . | | 0 |
| 205 | Abstract 5620: Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings.. , 2013, , . | | 0 |
| 206 | Abstract 5617: A new α V/ β 3 integrin selective carrier for nanodrug delivery to tumors based on isoDGR-tagged albumin.. , 2013, , . | | 0 |
| 207 | Abstract 1778: Characterization and anti-tumor functionality of a neuroblastoma-specific peptide, either free or conjugated to nanocarriers. , 2014, , . | | 0 |
| 208 | Vasostatin-1 as a potential novel circulating biomarker in patients with chronic systolic heart failure: A pilot study. <i>Clinica Chimica Acta</i> , 2022, 526, 49-54. | 1.1 | 0 |